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Accepted 12 September 2017Background: The PROspective Multicenter Imaging Study for Evaluation of chest pain (PROMISE) minimal-risk
tool was recently developed to identify patients with suspected stable angina at very low risk of coronary artery
disease (CAD) and clinical events.We assessed the external validity of this tool within the context of the Scottish
Computed Tomography of the HEART (SCOT-HEART) multicenter randomised controlled trial of patients with
suspected stable angina due to coronary disease.
Methods: Theminimal-risk toolwas applied to 1764patientswith complete imaging and follow-updata. External
validity was comparedwith the guideline-endorsed CAD Consortium (CADC) risk score and determined through
tests of model discrimination and calibration.
Results:A total of 531 (30.1%,meanage 52.4 years, female 62.0%) patientswere classiﬁed asminimal-risk. Compared
to the remainder of the validation cohort, this group had lower estimated pre-test probability of coronary disease
according to the CADCmodel (30.0% vs 47.0%, p b 0.001). The PROMISE minimal-risk tool improved discrimination
compared with the CADC model (c-statistic 0.785 vs 0.730, p b 0.001) and was improved further following re-
estimation of covariate coefﬁcients (c-statistic 0.805, p b 0.001). Model calibration was initially poor (χ2 197.6,
Hosmer-Lemeshow [HL] p b 0.001),with signiﬁcant overestimation of probability ofminimal risk, but improved sig-
niﬁcantly following revision of the PROMISEminimal-risk intercept and covariate coefﬁcients (χ2 5.6, HL p=0.692).
Conclusion and relevance: Despite overestimating the probability of minimal-risk, the PROMISE minimal-risk tool
outperforms the CADC model with regards to prognostic discrimination in patients with suspected stable angina,
and may assist clinicians in decisions regarding non-invasive testing.
Trial registration: ClinicalTrials.gov identiﬁer: NCT01149590aging
y of the
tery d
CE-PM
g.
re for
Franc
on).
land Lt© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
Stable angina
Coronary artery disease
Coronary computed tomography angiography1. Introduction
Chest pain is responsible for N1% of all presentations to family physi-
cians, although stable coronary artery disease (CAD) is the underlyingStudy for Evaluation of
HEART; CCTA, coronary
isease; CADC, Coronary
M, multiple imputation
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d. This is an open access articlcause in only a minority [1,2]. Increased community awareness of CAD
risk and improvements in primary prevention have led to progressively
lower disease prevalence within this patient population and the
frequency of abnormal results on ischaemia testing is now b10% [3].
There is a clear need to reﬁne the assessment of suspected stable angina
to optimise the efﬁcient use of diagnostic resources and minimise un-
necessary investigations. Recently, investigators from the North
American PROspective Multicenter Imaging Study for Evaluation of
chest pain (PROMISE) trial developed a risk model to identify
individuals at very low risk of CAD [4]. To investigate the generalisability
of this risk score, we undertook an external validation in a United
Kingdom-based study of computed tomography in the diagnosis
of CAD: the Scottish COmputed Tomography of the HEART (SCOT-
HEART) trial.e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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The SCOT-HEART studywas aprospectivemulticenter randomised controlled trial inves-
tigating the role of coronary computed tomography angiography (CCTA) in patients referred
to a specialist clinic with suspected angina due to CAD. The study design [5] and principal
ﬁndings [6] have previously been reported. Brieﬂy, participants were recruited from 12 car-
diology chest pain clinics across Scotland and those randomised to the intervention arm
underwent CCTA imaging in addition to routine clinical care. In contrast with PROMISE,
therewas a higher prevalence of obstructive coronary disease in the SCOT-HEART population
(25.4% vs 10.7%) [7]. For the purposes of this analysis, we limited the validation cohort to
those individuals randomised to assessmentwith CCTAwhohad sufﬁcient data to determine
minimal-risk. The mean period of follow-up was 3.3 ± 1.0 years.
Consistent with PROMISE [4], minimal-risk was deﬁned as requiring a coronary
calcium score of 0, no CCTA evidence of coronary atherosclerosis, and the absence of any
cardiovascular events (including all-cause death, non-fatal myocardial infarction or coro-
nary revascularisation) during follow-up. All variables included in the published model
were evaluated in this analysis with the exception of ethnicity because of the disparate
ethnic composition of the study populations. The remaining variables include: age, sex,
smoking history, diabetesmellitus, dyslipidemia, family history of premature coronary ar-
tery disease, hypertension, symptoms related to stress and high-density lipoprotein (HDL)
concentration. In caseswhereHDL-cholesterol concentrationswere not available,multiple
imputation using regression switching with predictive mean matching (MICE-PMM) was
employed [8].
Multivariable binomial logistic regression using the published model coefﬁcients was
used to estimate the probability ofminimal-risk for each participant and the predicted risk
was compared to the observed outcomes for these individuals. Model discrimination was
determined from area under the receiver-operator curve (AUC), or c-statistic, and com-
pared to the established CADConsortium (CADC) risk score,whichhas recently been dem-
onstrated to outperform the older Diamond-Forrester score [9,10]. The variables included
in the CADCmodel include age, sex and typicality of presenting symptoms (typical, atyp-
ical or non-anginal).Discrimination reﬂects the ability of themodel to correctly distinguish
between minimal-risk (no plaque and no events) and other-risk individuals (i.e. place all
subjects in the correct rank order of risk). Calibration describes the agreement between
predicted and observed likelihood of minimal risk for an individual. Model calibration
was assessed visually by plotting predicted versus observed risk in deciles and quantiﬁed
with the Hosmer-Lemeshow (HL) statistic. Tests of discrimination and calibration were
performed sequentially after step-wise updating of the model intercept (‘recalibration-
in-the-large’) and slope to allow for differences in baseline risk between the derivation
and validation populations. Finally, these tests were repeated following model revision,
retaining the initial covariates but with coefﬁcients re-estimated within the SCOT-
HEART cohort. Statistical analysis was performed using R version 3.3.0 (R Foundation for
Statistical Computing, Vienna, Austria).3. Results
Within the 2073 participants randomised to the intervention arm,
1778 underwent CCTA scanning. In total, 1764 patients (57.6, SD
9.5 years, female 44%) had complete imaging and outcome data avail-
able for analysis of whom 531 (30.1%; 52.4, SD 9.6 years, female
62.0%) fulﬁlled all criteria for minimal-risk (Supplementary Table 1).
High-density lipoprotein cholesterol (HDL-C) concentrations were un-
available in 506 patients (28.7%) and values were imputed.
In comparison with the remainder of the cohort, patients with
minimal-risk were less likely to have symptoms of typical angina
(24.1% vs 42.6%, p b 0.001) and had lower pre-test probability of ob-
structive CAD as determined from the CADC risk score (30.0% vs
47.0%, p b 0.001).
Table 1 reports the observed probability of minimal risk, ﬁndings on
CCTA, revascularisation and observed probability of all-cause death or
non-fatal myocardial infarction within the SCOT-HEART population
grouped by decile of predicted probability of no risk.
Model discrimination (Supplementary Fig. 1) was greater using the
PROMISE minimal-risk score compared with the CADC model (c-statistic
0.785, 95% conﬁdence interval [95% CI] 0.762–0.808, vs 0.730, 95% CI
0.706–0.755; p b 0.001). Discrimination was unaffected by re-calibration
of model intercept or slope but the c-statistic improved further
following revision of the model coefﬁcients (c-statistic 0.805, 95% CI
0.784–0.827; p b 0.001).
Goodness-of-ﬁt was not demonstrated for either established CADC
model (χ2 1010.1, HL p b 0.001) or the PROMISE minimal-risk risk tool
(χ2 197.6, HL p b 0.001). Goodness-of-ﬁt for the PROMISE minimal-risk
risk tool remained suboptimal following recalibration of themodel inter-
cept (χ2 32.2, HL p b 0.001) and calibration slope (χ2 23.7, HL p=0.026)but was improved by the further addition of re-estimated model coefﬁ-
cients (χ2 5.6, HL p= 0.692; Supplementary Table 2) resulting in good
calibration (Fig. 1).4. Discussion
When applied to the SCOT-HEART population, the PROMISE
minimal-risk tool improved model discrimination for excluding CAD
when compared with the established CADC model. Indeed, the present
c-statistic is greater than that reported in the original PROMISE model
derivation (0.785 versus 0.725) [4]. The improved discrimination of
the PROMISE score comparedwith the CADC score likely reﬂects the dif-
ferent intended purpose of these scores. The CADC model was derived
with the objective of accurately estimating the pre-test probability of
obstructive coronary artery disease whilst the PROMISE model adopts
a broader approach of excluding the presence of any coronary athero-
sclerosis or any clinical events throughout follow-up.
Model calibration – i.e. the ability to estimate accurately an individ-
uals' absolute risk – was poor when applied in the SCOT-HEART trial
population. Such a ﬁnding is common when assessing model perfor-
mance in clinically divergent settings [11–14] and causes may be
patient-related (including differences in case-mix, event rates, or pre-
dictor deﬁnitions), or model-related, such as over (or under-) ﬁtting
of coefﬁcients or omission of important predictive variables.
Poor goodness-of-ﬁt does not necessarily signify lack ofmodel value,
and the robust discrimination demonstrated in this report suggests ap-
propriate and informative covariate selection. Therefore, we adopted
the recommended stepwise approach to model updating [11] that suc-
cessfully improved model calibration within the SCOT-HEART popula-
tion. It is plausible, that the PROMISE risk model remains correct in its
initial form for application within the North American context, whilst
the updated coefﬁcients may provide more accurate risk estimates for
Europeanpopulations. Regardless, to achieve accurate predictions of ab-
solute risk, it is likely that such population-speciﬁc recalibration would
be desirable for each setting in which the model was to be applied.
However, even in the absence of this recalibration, ourﬁndings have im-
portant implications for determining appropriate diagnostic pathways
and highlight that clinicians need to be aware of the imprecision of
the estimates determined from the minimal-risk score. In recognition
of this, the current guidelines for prevention of atherosclerotic cardio-
vascular disease already recommend incorporating explanation of the
uncertainty of prognostic models in the clinician-patient risk discussion
[15].
In order to understand the reasons for risk estimate imprecision we
need to consider carefully the differences in patient populations between
the PROMISE and SCOT-HEART trials. Such differences have previously
been reported [16], but speciﬁc areas of relevance to the current ﬁndings
warrant mention. First, the improvement in discrimination seen with the
SCOT-HEART population is likely to reﬂect the greater breadth of baseline
risk which gives rise to a broader spread of the linear predictors within
the validation cohort [17]. Relatedly, there is an apparent difference in
the proportion of the trial populations fulﬁlling the criteria for minimal-
risk between the studies, with slightly more low-risk patients identiﬁed
in the SCOT-HEART cohort. This ‘miscalibration-in-the-large’ is a frequent
challenge but can be straightforwardly addressed, if the average patient
risk is known within the external clinical setting in which the model is
being applied, by adjustment of the model intercept. Furthermore, al-
though the exact nature of the effects of this difference in case-mix or
‘spectrum bias’ is difﬁcult to quantify, some insight can be gained from
examination of the change in speciﬁc variable coefﬁcients. With one
exception, all the coefﬁcients increased in magnitude when re-
estimated. Those covariates where the increase was most substantial,
for example female sex, appear to be more powerful predictors of
minimal-risk in the SCOT-HEART population than was identiﬁed in
PROMISE.
Table 1
Test results and event rates by probability of minimal risk.
Predicted probability
of no risk
N Observed probability
of no risk, SD
Findings on CCTA Revascularisation Death or
MI
Normal Mild
disease
Moderate
disease
Obstructive
disease
0.0–0.1 2 (0.1) 0.00 (0.00) 0 (0.0) 0 (0.0) 0 (0.0) 2 (100.0) 1 (50.0) 0 (0.0)
0.1–0.2 168 (9.5) 0.02 (0.15) 7 (4.2) 27 (16.1) 41 (24.4) 93 (55.4) 43 (25.6) 17 (10.1)
0.2–0.3 313 (17.7) 0.12 (0.33) 54 (17.3) 72 (23.0) 63 (20.1) 124 (39.6) 72 (23.0) 10 (3.2)
0.3–0.4 322 (18.3) 0.18 (0.38) 82 (25.5) 79 (24.5) 55 (17.1) 106 (32.9) 65 (20.2) 10 (3.1)
0.4–0.5 278 (15.8) 0.22 (0.41) 82 (29.5) 68 (24.5) 58 (20.9) 70 (25.2) 41 (14.7) 8 (2.9)
0.5–0.6 250 (14.2) 0.40 (0.49) 115 (46.0) 63 (25.2) 41 (16.4) 31 (12.4) 17 (6.8) 6 (2.4)
0.6–0.7 221 (12.5) 0.56 (0.50) 138 (62.4) 37 (16.7) 27 (12.2) 19 (8.6) 10 (4.5) 3 (1.4)
0.7–0.8 137 (7.8) 0.66 (0.47) 103 (75.2) 15 (10.9) 15 (10.9) 4 (2.9) 1 (0.7) 2 (1.5)
0.8–0.9 60 (3.4) 0.75 (0.44) 50 (83.3) 7 (11.7) 2 (3.3) 1 (1.7) 1 (1.7) 0 (0.0)
0.9–1.0 13 (0.7) 1.00 (0.00) 13 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Data is presented as number (percentage) of patients unless otherwise stated.
SD, standard deviation; CCTA, coronary computed tomography angiography; MI, myocardial infarction.
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viously deﬁned and broadly accepted threshold of risk that suitably as-
sists clinicians in identifying those patientswho can have further testing
safely deferred. In this regard, the accuracy of absolute predicted risk
may be of secondary importance to how reliably a model categorizes
or reclassiﬁes an individual into appropriate diagnostic pathways. In
the absence of updated clinical guidelines incorporating the minimal-
risk tool, it is unclear where this threshold should be set. However, it
is reassuring to note that the probability of obstructive coronary artery
disease remainsb10% in thehighest four deciles of predicted probability
ofminimal risk, whilst the corresponding risk of death ormyocardial in-
farction remains below 2% in these groups. International guidelines
have previously adopted low-risk thresholds in this range, below
which further investigation is unhelpful [18,19]. Should such an ap-
proach be continued using the PROMISE model, it would identify 1 in
4 patients who could safely avoid further testing, enabling potentially
important reductions in diagnostic resource use.0.0
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Fig. 1.Model calibration. Plot demonstrates poor calibration of predicted probability vs
observed proportion of minimal risk using initial model coefﬁcients and intercept (blue)
in addition to the established Coronary Artery Disease Consortium (CADC) model
(green). Calibration remains poor despite updating the model intercept (grey) and slope
(purple). Good model calibration (HL, Hosmer-Lemeshow) is demonstrated once the
model coefﬁcients are re-estimated within the validation cohort (red). The dashed line
represents perfect calibration [22].It should be noted that within the United Kingdom, the National In-
stitute for Health and Care Excellence (NICE) has recently updated guid-
ance for the diagnosis of suspected stable angina [20]. This guideline has
endorsed a shift to a symptom-focused approach to chest pain assess-
ment,moving away from thebroader cardiovascular risk-based strategy
previously recommended [19]. Such an approach appears to more ap-
propriately target the use of non-invasive testing and improve clinical
outcomes [21]. Whether the cardiovascular risk assessment provided
by the PROMISE risk tool can offer advantages to the NICE approach re-
mains unclear and would need to be prospectively determined.
This study has some limitations. Failure to undergo CCTA as
randomised, non-diagnostic images and the absence of coronary calcium
scans, precluded the determination of minimal-risk in 309 (14.9%) pa-
tients. HDL-C concentrations were not available in a ﬁfth of patients al-
though the MICE-PMM technique for imputation achieves minimally
biased estimates and satisfactory model performance with up to 50%
missingness [8]. Finally, we excluded unstable angina not leading to
revascularisation as a minimal risk exclusion criterion since unlike
PROMISE, unstable angina events were not adjudicated in SCOT-HEART.
However, with the widespread use of high-sensitivity troponin in
Scotland, unstable angina accounts for b5% of all acute coronary
syndromes.
5. Conclusion
When assessing patients with suspected stable angina, the PROMISE
minimal-risk tool outperforms the CADCmodel and improves discrimi-
nation of the pre-test probability of normal coronary arteries and no
clinical events. Suboptimal model calibration may overestimate proba-
bility of minimal risk in external populations. Nevertheless, the
PROMISE minimal-risk tool may assist clinicians in decisions regarding
non-invasive testing.
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